AMA1

Open Access | Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine

Author(s):

Ouattara A, Mu J, Takala-Harrison S, Saye R, Sagara I, Dicko A, Niangaly A, Duan J, Ellis RD, Miller LH, Su X, Plowe CV, Doumbo OK

Reference:

Malaria Journal 2010, 9:175 (21 June 2010)

This Phase 2 trial of a bivalent AMA1 malaria vaccine found no evidence of vaccine selection or strain-specific efficacy, suggesting that the extreme genetic diversity of AMA1 did not account for failure of the vaccine to provide protection.

Person:

Medical Condition:

Medical Treatment:

Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults

Author(s):

Mark A. Pierce, Ruth D. Ellis, Louis H. Miller et al.

Reference:

Vaccine, Volume 28, Issue 10, 2 March 2010, Pages 2236-2242

A Phase 1 trial was conducted in malaria-naïve adults to evaluate the recombinant protein vaccine apical membrane antigen 1-Combination 1 (AMA1-C1) formulated in Montanide® ISA 720 (SEPPIC, France), a water-in-oil adjuvant.

Technology:

Medical Condition:

Medical Treatment:

Open Access | Safety and Immunogenicity of an AMA1 Malaria Vaccine in Malian Children: Results of a Phase 1 Randomized Controlled Trial

Author(s):

Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Kone AK, et al.

Reference:

PLoS ONE 5(2): e9041

The FMP2.1/AS02A vaccine had a good safety profile, was well-tolerated, and induced high and sustained antibody levels in malaria-exposed children. This malaria vaccine is being evaluated in a Phase 2 efficacy trial in children at this site.

Technology:

Country:

Medical Condition:

Medical Treatment:

Search form

You are here